

Sustainability Report

2024



Mitsubishi Tanabe Pharma



MITSUBISHI
CHEMICAL
GROUP

Contents

Editorial Policies	1	Society	
Mitsubishi Tanabe Pharma's Sustainability	2	Together with Patients and Healthcare Professionals	
Materiality	3	Research & Development	48
Stakeholder Engagement	10	Stable Supply	51
		Manufacturing Pharmaceuticals that are Secure, Safe, and Convenient to Use	55
Management		Information Provision	59
Code of Conduct	11	Drug Safety / Quality Assurance	68
Respect for Human Rights	12	Solving Issues Related to Improving Access to Healthcare	72
R&D Ethics	15	Together with Employees	
Compliance	16	Human Resources Development	77
Risk Management	18	Promoting Diversity & Inclusion	81
Promotion of Fair Operating Practices	20	Work-Style Innovation	89
		Occupational Health and Safety	92
Environment		Health and Productivity Management	96
Environmental Management	24	Together with Business Partners	
Targets & Initiatives	29	Establishment of a Sustainable Supply Chain	108
Climate Change Initiatives	33	Together with Local Communities and Society	
Water Resource Initiatives	38	Corporate Citizenship Policy	111
Initiatives to Reduce Waste and Recycle Resources	39	Contributions to Medical Care and Welfare	112
Initiatives to Prevent Pollution	41	Development of Science and Technology	119
Biodiversity Initiatives	44	Contributions to the Environment	120
Environmental Accounting	47	Promotion of Local Communities	123
		Activities Addressing Social Needs	129
		Other Related Information	
		External Evaluations	134
		Data	136
		GRI Standard Comparative Table	153
		Explanation of Terms	159
		Company Overview 2024	161



Editorial Policies

This website is intended to provide the Group's stakeholders, including patients, healthcare professionals, local communities, and employees, with information about major sustainability initiatives implemented by the Group in fiscal 2023. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with management, the environment, and society. Additionally, it also features descriptions of initiatives and activities of the Mitsubishi Chemical Group (the MCG Group).

The Sustainability Report 2024 PDF version, which contains the same content as disclosed on this website, can be downloaded from [the Sustainability Report archive page](#).

[Explanations of medical and pharmaceutical terms](#) appearing in this report have been provided to foster a wider understanding of the report's content.

Applied Guidelines	<ul style="list-style-type: none">• Global Reporting Initiative (GRI) Sustainability Reporting Standard;• Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan
Period covered	April 1, 2023, to March 31, 2024 (The report includes examples of activities from April 2024 and thereafter)
Issue timing	September 2024 (Previous report: September 2023; next report: September 2025)
Scope of reporting	Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas. (The scope of reporting could differ in accordance with the examples being reported.)
Contact information	> Contact Us